Could a common ADHD drug sharpen focus and boost quality of life for veterans with PTSD?

NCT ID NCT06573970

Recruiting now Symptom relief Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study tests whether atomoxetine, a non-addictive ADHD medication, can improve attention, thinking skills, and quality of life in 160 veterans with PTSD who also have attention problems. Participants will receive either atomoxetine or a placebo for 12 weeks. The goal is to see if treating attention deficits helps veterans respond better to PTSD care and feel better day-to-day.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTTRAUMATIC STRESS DISORDER WITH ATTENTION DEFIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTTRAUMATIC STRESS DISORDER WITH ATTENTION DEFIC

Contacts and locations

Locations

Ralph H. Johnson VA Medical Center, Charleston, SC
RECRUITING

Charleston, South Carolina, 29401-5703, United States